564 related articles for article (PubMed ID: 18173693)
21. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
[TBL] [Abstract][Full Text] [Related]
22. Desmopressin does not decrease blood loss and transfusion requirements in patients undergoing hepatectomy.
Wong AY; Irwin MG; Hui TW; Fung SK; Fan ST; Ma ES
Can J Anaesth; 2003 Jan; 50(1):14-20. PubMed ID: 12514144
[TBL] [Abstract][Full Text] [Related]
23. Response to desmopressin of factors XI, X and V in patients with factor VIII deficiency and von Willebrand disease.
White B; Lawler P; Riddell A; Nitu-Whalley IC; Hermans C; Lee CA; Brown SA
Br J Haematol; 2004 Jul; 126(1):100-4. PubMed ID: 15198739
[TBL] [Abstract][Full Text] [Related]
24. Laboratory diagnosis and molecular classification of von Willebrand disease.
Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
[TBL] [Abstract][Full Text] [Related]
25. A point-of-care assessment of the effects of desmopressin on impaired platelet function using multiple electrode whole-blood aggregometry in patients after cardiac surgery.
Weber CF; Dietrich W; Spannagl M; Hofstetter C; Jámbor C
Anesth Analg; 2010 Mar; 110(3):702-7. PubMed ID: 20042444
[TBL] [Abstract][Full Text] [Related]
26. Desmopressin has no beneficial effect on excessive postoperative bleeding or blood product requirements associated with cardiopulmonary bypass.
de Prost D; Barbier-Boehm G; Hazebroucq J; Ibrahim H; Bielsky MC; Hvass U; Lacombe C; Français JL; Desmonts JM
Thromb Haemost; 1992 Aug; 68(2):106-10. PubMed ID: 1412152
[TBL] [Abstract][Full Text] [Related]
27. Intranasal desmopressin versus blood transfusion in cirrhotic patients with coagulopathy undergoing dental extraction: a randomized controlled trial.
Stanca CM; Montazem AH; Lawal A; Zhang JX; Schiano TD
J Oral Maxillofac Surg; 2010 Jan; 68(1):138-43. PubMed ID: 20006168
[TBL] [Abstract][Full Text] [Related]
28. Hyponatremia after desmopressin (DDAVP) use in pediatric patients with bleeding disorders undergoing surgeries.
Sharma R; Stein D
J Pediatr Hematol Oncol; 2014 Aug; 36(6):e371-5. PubMed ID: 24942016
[TBL] [Abstract][Full Text] [Related]
29. Mechanisms of platelet dysfunction and response to DDAVP in patients with congenital platelet function defects. A double-blind placebo-controlled trial.
Rao AK; Ghosh S; Sun L; Yang X; Disa J; Pickens P; Polansky M
Thromb Haemost; 1995 Oct; 74(4):1071-8. PubMed ID: 8560416
[TBL] [Abstract][Full Text] [Related]
30. [Von Willebrand disease: from diagnosis to treatment].
Fressinaud E; Meyer D
Rev Prat; 2005 Dec; 55(20):2209-18. PubMed ID: 16519045
[TBL] [Abstract][Full Text] [Related]
31. Desmopressin for the treatment of haemophilia.
Castaman G
Haemophilia; 2008 Jan; 14 Suppl 1():15-20. PubMed ID: 18173690
[TBL] [Abstract][Full Text] [Related]
32. Highly purified VWF/FVIII concentrates in the treatment and prophylaxis of von Willebrand disease: the PRO. WILL Study.
Federici AB
Haemophilia; 2007 Dec; 13 Suppl 5():15-24. PubMed ID: 18078393
[TBL] [Abstract][Full Text] [Related]
33. Adventures in hemostasis. Desmopressin in cardiac surgery.
Salzman EW; Weinstein MJ; Reilly D; Ware JA
Arch Surg; 1993 Feb; 128(2):212-7. PubMed ID: 8431122
[TBL] [Abstract][Full Text] [Related]
34. Prophylaxis in von Willebrand disease.
Franchini M; Targher G; Lippi G
Ann Hematol; 2007 Oct; 86(10):699-704. PubMed ID: 17634944
[TBL] [Abstract][Full Text] [Related]
35. Desmopressin does not decrease bleeding after cardiac operation in young children.
Reynolds LM; Nicolson SC; Jobes DR; Steven JM; Norwood WI; McGonigle ME; Manno CS
J Thorac Cardiovasc Surg; 1993 Dec; 106(6):954-8. PubMed ID: 8246577
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of high concentration intranasal and intravenous desmopressin in pediatric patients with mild hemophilia A or mild-to-moderate type 1 von Willebrand disease.
Gill JC; Ottum M; Schwartz B
J Pediatr; 2002 May; 140(5):595-9. PubMed ID: 12032528
[TBL] [Abstract][Full Text] [Related]
37. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA).
Nichols WL; Hultin MB; James AH; Manco-Johnson MJ; Montgomery RR; Ortel TL; Rick ME; Sadler JE; Weinstein M; Yawn BP
Haemophilia; 2008 Mar; 14(2):171-232. PubMed ID: 18315614
[TBL] [Abstract][Full Text] [Related]
38. Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays?
Favaloro EJ; Thom J; Patterson D; Just S; Dixon T; Koutts J; Baccala M; Rowell J; Baker R
Thromb Res; 2009 Apr; 123(6):862-8. PubMed ID: 19064279
[TBL] [Abstract][Full Text] [Related]
39. Laboratory diagnosis and monitoring of desmopressin treatment of von Willebrand's disease by flow cytometry.
Giannini S; Mezzasoma AM; Leone M; Gresele P
Haematologica; 2007 Dec; 92(12):1647-54. PubMed ID: 18055988
[TBL] [Abstract][Full Text] [Related]
40. Use of desmopressin to prevent bleeding in surgery.
Flordal PA
Eur J Surg; 1998 Jan; 164(1):5-11. PubMed ID: 9537702
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
